Open AccessWhat MELD score mandates use of entecavir for ACLF-HBV HBeAg-negative patients?
Author(s) -
Ying Yan,
Mai Li,
Yubao Zheng,
Shaoquan Zhang,
Wenxiong Xu,
Zhiliang Gao,
Wei-Min Ke
Publication year - 2012
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v18.i33.4604
Subject(s) - entecavir , medicine , hbeag , gastroenterology , regimen , hepatitis b virus , hepatitis b , viral load , hepatitis a virus , liver disease , immunology , lamivudine , hbsag , virus
To investigate optimal timing for therapeutic efficacy of entecavir for acute-on-chronic hepatitis B liver failure (ACLF-HBV) in hepatitis B e antigen (HBeAg)-negative patients.